Mesirow Institutional Investment Management Inc. Acquires 29,774 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mesirow Institutional Investment Management Inc. lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 24.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 153,797 shares of the medical equipment provider's stock after acquiring an additional 29,774 shares during the period. Mesirow Institutional Investment Management Inc. owned 0.22% of Lantheus worth $13,759,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MetLife Investment Management LLC boosted its holdings in Lantheus by 7.6% in the fourth quarter. MetLife Investment Management LLC now owns 79,521 shares of the medical equipment provider's stock valued at $7,114,000 after purchasing an additional 5,621 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Lantheus by 7.7% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 99,060 shares of the medical equipment provider's stock valued at $8,862,000 after acquiring an additional 7,043 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Lantheus by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after acquiring an additional 30,891 shares during the last quarter. First Trust Advisors LP lifted its stake in Lantheus by 9.8% during the fourth quarter. First Trust Advisors LP now owns 87,300 shares of the medical equipment provider's stock worth $7,810,000 after purchasing an additional 7,827 shares in the last quarter. Finally, Alpha Wave Global LP acquired a new stake in Lantheus during the 4th quarter worth approximately $6,478,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on LNTH shares. JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 over the last three months. 2.00% of the stock is owned by corporate insiders.

Lantheus Price Performance

NASDAQ LNTH traded down $2.30 on Friday, hitting $101.34. 296,689 shares of the company were exchanged, compared to its average volume of 865,464. The firm has a market capitalization of $6.94 billion, a P/E ratio of 16.92 and a beta of 0.20. Lantheus Holdings, Inc. has a twelve month low of $65.08 and a twelve month high of $126.89. The company's 50 day moving average price is $97.01 and its 200-day moving average price is $95.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.